REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Peptide Therapy Shows Promise in Combating Opioid Use Disorder
Back to Research Library

Peptide Therapy Shows Promise in Combating Opioid Use Disorder

May 25, 2026
Share
Emerging Research

Based on emerging research. These findings are promising but require further validation.

About This Analysis

This article is an AI-assisted summary of a recently published news item or clinical trial listing. It is intended to provide a quick, accessible overview for the peptide research community. For full accuracy, always refer to the original source linked below.

Peptide Therapy Shows Promise in Combating Opioid Use Disorder

Recent developments in peptide research have sparked interest with a new clinical trial evaluating tirzepatide as an adjunct treatment for individuals struggling with opioid use disorder (OUD). The study, led by Dr. T. John Winhusen and sponsored through the National Institute on Drug Abuse (NIDA), aims to assess whether adding tirzepatide can improve outcomes when used alongside buprenorphine.

Background

Peptide therapy has been gaining traction in medical research due to its potential for targeted treatment approaches that minimize side effects. Tirzepatide, a GLP-1 receptor agonist and GIP receptor antagonist, is currently approved by the FDA for treating type 2 diabetes and obesity but shows promise beyond these applications. Research suggests it may have neuroprotective properties beneficial in managing addiction.

Opioid use disorder affects millions of people worldwide, with buprenorphine being a standard treatment option that helps mitigate withdrawal symptoms and reduces cravings. However, many patients find the need for additional support to fully recover from OUD. The introduction of tirzepatide as an adjunct therapy could provide a new avenue for enhancing patient outcomes.

Key Details

The research study, currently recruiting participants through ClinicalTrials.gov under identifier NCT06651177, focuses on evaluating the impact of tirzepatide compared to placebo in patients with OUD. This Phase 2 trial will investigate how adding tirzepatide influences retention rates in treatment programs, substance use patterns, and sleep quality.

Participants will be monitored over an extended period to assess if combining buprenorphine with tirzepatide can lead to better long-term outcomes compared to using buprenorphine alone. The study emphasizes the importance of addressing multiple facets of OUD recovery, including psychological support and pharmacological intervention.

Key Takeaways

  • Novel Adjunct Therapy: This trial explores the potential benefits of using tirzepatide alongside established treatments like buprenorphine.
  • Improved Outcomes: Researchers aim to determine if adding a peptide therapy can enhance patient retention in treatment programs and reduce substance use.
  • Sleep Quality Assessment: The study also focuses on evaluating sleep patterns, recognizing their critical role in overall recovery from OUD.
  • Scientific Community Interest: This research could attract significant attention within the scientific community due to its innovative approach combining established treatments with new peptide therapies.

What This Means

For the peptide therapy and research community, this trial represents a pivotal moment. If successful, it would highlight the versatility of peptides in addressing complex medical conditions beyond their current applications. Additionally, the findings could pave the way for regulatory bodies like the FDA to consider approving similar adjunctive treatments for OUD.

Moreover, the study underscores the growing importance of integrating multi-faceted approaches in treating addiction and mental health disorders. As peptide research continues to advance, such innovative clinical trials will likely become more common, offering hope to patients seeking effective treatment options.

---

Source: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06651177) — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

Editor's Note

This analysis was generated using AI tools and reviewed by the Peptide Contacts editorial team. While we strive for accuracy, AI-generated content may contain errors or omissions. We encourage readers to review the original source for complete details, methodology, and data.

Peptide Contacts provides curated research summaries for informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider before making any health decisions.

Comments

Sign in to join the discussion

This article was generated using AI and may contain inaccuracies. It is provided for informational purposes only and does not constitute medical advice. Always verify information with the original source and consult a qualified healthcare provider before making any health decisions.